Want to see URGN full AI Analyst Report?
URGN Stock Chart & Stats
$22.54
-$0.02(-0.18%)
At close: 4:00 PM EST
$22.54
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$15.35 - $43.93
Previous CloseN/A
Volume157.75K
Average Volume (3M)741.63K
Market Cap
$2.00B
Enterprise Value$957.78
Total Cash (Recent Filing)$141.60M
Total Debt (Recent Filing)$197.09M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 06, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding48,721,703
10 Day Avg. Volume892,170
30 Day Avg. Volume741,633
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)-10.68
Price to Sales (P/S)10.26
P/FCF Ratio-6.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$41.50Price Target Upside84.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$276.49M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth & High Gross MarginsSustained top-line expansion combined with very high gross margins indicates the business has favorable unit economics and growing market adoption. Over several quarters this supports scalable gross profit potential, giving the company a structural ability to improve operating leverage as commercial scale increases.
ZUSDURI Early Commercial TractionRapid prescriber additions, rising repeat use and meaningful Q1 revenue signal product-market fit and a functioning commercial model. Improving PEF‑to‑start cycle times and a shift toward community channels support more durable prescription growth and broadened addressable reach over the next several months.
Pipeline Progress And Upcoming Regulatory CatalystsClear, near-term regulatory milestones across multiple programs diversify the company’s product roadmap beyond existing assets. Successful filings/approvals would materially expand long-term revenue potential and reduce single-product dependency, strengthening the company’s structural growth profile over 12–24 months.
Bears Say
Large, Persistent Cash BurnConsistently large negative operating and free cash flows indicate the company is consuming significant cash to fund launches and operations. This structurally increases dependence on external financing, heightens dilution or leverage risk, and constrains reinvestment flexibility until cash generation improves.
Weak Balance Sheet: Negative Equity And Rising DebtNegative shareholder equity alongside materially higher debt reduces financial flexibility and elevates refinancing and covenant risk. Higher leverage raises fixed costs and limits the firm's ability to absorb setbacks or invest opportunistically, making the capital structure a persistent fundamental vulnerability.
High Launch SG&A And Limited Near-term Revenue VisibilityElevated SG&A spending to support the ZUSDURI launch compresses operating leverage and delays profitability. Coupled with low current prescriber penetration and no formal full‑year ZUSDURI guidance, this creates structural uncertainty about the speed at which scale reduces losses and converts high gross profit into durable net earnings.
Urogen Pharma News
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $15.35 and its highest was $43.93 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $2.00B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Aug 06, 2026 which is in 14 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on May 06, 2026. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.482 by $0.012.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -0.27.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 48,721,703 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.482. Following the earnings report the stock price went up 10.155%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in URGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.50 (84.12% Upside)
$41.50 (84.12% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 28.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
169.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.45%
Trailing 12-Months
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
URGN Stock 12 Month Forecast
Average Price Target
$41.50
▲(84.12% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
1.90% Insiders
5.17% Mutual Funds
0.82% Other Institutional Investors
84.94% Public Companies and
Individual Investors